Centessa Pharmaceuticals to be Acquired by Eli Lilly for Up to $7.8 Billion, Including CVRs

summarizeSummary

Centessa Pharmaceuticals has entered into a definitive agreement to be acquired by Eli Lilly for an upfront cash payment of $38.00 per share plus contingent value rights (CVRs) worth up to an additional $9.00 per share, totaling up to $47.00 per share.

check_boxKey Events

• Acquisition Agreement

  Centessa Pharmaceuticals has entered into a definitive agreement to be acquired by Eli Lilly for a total potential equity value of up to approximately $7.8 billion.

• Shareholder Payout Structure

  Shareholders will receive $38.00 per share in cash at closing, plus one contingent value right (CVR) representing the right to receive potential milestone payments in an aggregate amount of up to $9.00 per share.

• Significant Premium

  The cash consideration payable at closing represents a premium of approximately 40.5% to Centessa's 30-day volume-weighted average trading price ended on March 30, 2026.

• Strategic Rationale

  Eli Lilly recognizes the strength and potential of Centessa's science and programs, particularly its orexin portfolio, to advance its neuroscience indications.

auto_awesomeAnalysis

This definitive agreement for acquisition by Eli Lilly represents a significant positive outcome for Centessa shareholders, offering a substantial premium over recent trading prices. The transaction, valued at up to $7.8 billion, includes an upfront cash component and additional potential payments via CVRs tied to regulatory milestones for Centessa's orexin 2 receptor agonist product candidates. This strategic move by Eli Lilly aims to advance its neuroscience portfolio, while Centessa employees will see accelerated vesting of equity awards upon closing. The acquisition is expected to close in Q3 2026, subject to shareholder and regulatory approvals.